Royalty Pharma and Cytokinetics form $575m strategic funding collaboration for aficamten and cardiovascular pipeline.
Royalty Pharma and Cytokinetics have entered a strategic funding collaboration worth up to $575m to support the commercialization of aficamten and advance cardiovascular pipeline. This partnership diversifies Cytokinetics' access to capital as they advance their muscle biology-directed specialty cardiology business. This is Royalty Pharma's third transaction with Cytokinetics.
May 22, 2024
3 Articles